• Mashup Score: 4

    A brand-new, well-financed genome analysis company called Orchid made a splash last week : Orchid Blooms With $4.5M Seed For Preconception Test To Determine Genetic Risks (Kudos to the doubly punning headline writer at Crunchbase .) The concept is that Orchid will analyze “100% of both partners’ genomes” and analyze the possible ways they can combine “in a future child.”…

    Tweet Tweets with this article
    • Orchid is the latest company to offer polygenic embryo screening to prospective parents. But the scientific basis is deeply flawed, the social implications are appalling, & previous attempts to commercialize polygenic genome data have not been successful. https://t.co/r1WwsLUQlu https://t.co/QB9jkXxkGK

  • Mashup Score: 0

    Dominic Cummings, Boris Johnson’s former brain (he was forced out last November), claims not to know what eugenics is. This is odd, since he’s been called out for advocating it for years (here’s our 2013 take on his fondness for technocratic eugenics).  His implausible denial came during questioning on March 17 before the UK Parliament’s science and technology committee. MP…

    Tweet Tweets with this article
    • In testimony before the UK Parliament’s science and technology committee, Dominic Cummings (formerly Johnson’s brain) implausibly denied knowing what eugenics is. https://t.co/GEOKSKAEN1 1/2

  • Mashup Score: 0

    At least five separate studies involving human embryo research are raising fresh versions of old questions about science, ethics and regulation. On March 17, Nature published two peer-reviewed papers about generating in vitro, with slightly different methods, “blastoids” or “human blastocyst-like structures .” (One team, perhaps trying to be cute, called them “iBlastoids” but the…

    Tweet Tweets with this article
    • At least five separate studies involving #embryo research in humans and mice are raising fresh versions of old questions about science, ethics, and regulation. https://t.co/g8zGXOHyuE

  • Mashup Score: 5

    In recent weeks, at least four publications (1 , 2 , 3 , 4 ) have urged a change to the “14-day rule” that represents a widely accepted limit on in vitro research involving the cultivation of human embryos. Some call for changing the limit to 28 days , another suggests “increments of 2 or 3 days,” up to at least 18 days. The Hastings Center recently issued a Report on Rethinking…

    Tweet Tweets with this article
    • The 14-day limit on research with in vitro human embryos went unquestioned for years – until keeping them alive longer became technically possible. https://t.co/t2nZkLXc7U https://t.co/IaPIPZWyaa

  • Mashup Score: 0

    We were shocked — shocked — to learn that 23andMe is cashing in on its customers’ spit. $3.5 billion , the company is worth, they say, now that it’s going public. That is an awful lot of $99 gene tests! Except that the business model is not, and never has been, about cash flow from individual customers. No, the big money is in leasing out genetic data to pharmaceutical companies…

    Tweet Tweets with this article
    • 23andMe is going public in a deal valued at $3.5 billion. Its business model has never been about selling spit kits. The big money is in leasing out its customers’ genetic data to pharmaceutical companies and other researchers. https://t.co/DmfkAfmg4Q

  • Mashup Score: 1

    “Black-footed Ferret Kits”  by USFWS Mountain Prairie is licensed under CC BY 2.0 The New York Times published on February 18 an enthusiastic article about a black-footed ferret, hailing it as “the first of any native, endangered animal species in North America to be cloned.” As we have been documenting for many years (see below), grand claims for animal cloning go back to…

    Tweet Tweets with this article
    • Grand claims for animal cloning go back to the birth of the first cloned sheep in 1996. Advocates of “de-extinction” promote it as a way to save endangered species, though many believe that such efforts are, at best, counterproductive. https://t.co/Nm3atww8iH https://t.co/VaApPm8CkJ

  • Mashup Score: 0

    On Sunday, January 31, 60 Minutes featured DNA databases and China — together and separately — in fine, bombastic style. The flavor of the program is typified in the introduction to the second of its three main segments: The quest to control our biodata – and, in turn, control health care’s future – has become the new space race, with more than national pride in the…

    Tweet Tweets with this article
    • .@60Minutes featured interviews w/ @UCDavisLaw professor & @C_G_S Fellow Lisa Ikemoto & 23andMe CEO Anne Wojcicki. The segment focused on companies and countries — especially China — “vying for your DNA.” https://t.co/Q9yNXHB6QX

  • Mashup Score: 0

    The United States fertility market is growing very rapidly, and is projected to reach $15.4 billion in 2023, more than double what it was in 2017. That increase derives partly from a larger customer base and partly from a considerable expansion of the services being sold. Yet the sector remains curiously under-regulated, despite many calls to confront the numerous known issues,…

    Tweet Tweets with this article
    • New data on US #fertility clinics confirm the limitations of current law. Meanwhile, some clinics expand sales of expensive, unregulated techniques. Will this situation lead the way to a high-tech form of #eugenics? https://t.co/V17Hn3OOIH